Fetal globin stimulant therapies in the beta-hemoglobinopathies: Principles and current potential

Pediatric Annals

Volumn 37, Issue 5, 2008, Pages 339-346

  Perrine, Susan P ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HemaQuest Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE BUTYRATE; ARGININE DERIVATIVE; AZACITIDINE; BUTYRIC ACID; ERYTHROPOIETIN; HEMOGLOBIN F; HISTONE DEACETYLASE INHIBITOR; HQK 1001; HYDROXYUREA; IRON; ISOBUTYRAMIDE; SHORT CHAIN FATTY ACID; SHORT CHAIN FATTY ACID DERIVATIVE; SODIUM PHENYLBUTYRATE;

BETA THALASSEMIA; CELL SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; ERYTHROID CELL; ERYTHROPOIESIS; HEMOGLOBIN SYNTHESIS; HEMOGLOBINOPATHY; HUMAN; IRON THERAPY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SICKLE CELL ANEMIA;

EID: 45349107618     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/00904481-20080501-10     Document Type: Review

References (64)

1. Steinberg MH, Rodgers GP. Pharmacologic modulation of fetal hemoglobin. Medicine (Baltimore). 2001;80(5):328-344.
2. Steinberg MH. Predicting clinical severity in sickle cell anemia. Brit J Haematol. 2005;129(4): 465-481.
3. Perrine RP, Brown MJ, Clegg JB, Weatherall DJ, May A. Benign sickle anemia. Lancet. 1972;2(7788):1163-1167.
4. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11-16.
5. Platt OS, Brambilla DJ, Rosse WF, Milner PF, et al. Mortality in sickle cells disease: Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
6. Noguchi CT, Rodgers GP, Sergeant G, Schlechter AN. Levels of fetal hemoglobin necessary for treatment of in sickle cell disease. N Engl J Med. 1988;318(2):96-99.
7. Franco RS, Yasin Z, Palasacak MB, Ciraolo P, Joiner CH, Rucknagel DL. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood. 2006;108(3):1073-1076.
8. Perrine SP. Fetal globin induction - can it cure beta-thalassemia? Amer Soc Hematol Education Program. 2005;38-44.
9. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135-1146.
10. Gallo E, Massero P, Miniero R, David D, Tarella C. The importance of the genetic picture and globin synthesis in determining the clinical and hematological features of thalassemia intermedia. Br J Haematol. 1979;41(2):211-221.
11. Schrier SL. Pathobiology of thalassemic erythrocytes. Curr Opin Hematol. 1997;4(2):75-78.
12. Mathias LA, Fisher TC, Zeng L, et al. Ineffective erythropoiesis in beta-thalassemia major is due to apoptosis at the polychromatophilic nomoblast stage. Exp Hematol. 2000;28(12):1343-1353.
13. Yuan J, Angelucci E, Lucarelli G, et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia. Blood. 1993;82(7):374-377.
14. Galanello R, Barella S, Turco MP, et al. Serum erythropoietin levels and erythropoiesis in high and low-fetal hemoglobin beta-thalassemia intermedia patients. Blood. 1994;83(2):561-565.
15. Koury MJ, Sawyer ST, Brandt SJ. New insights into erythropoiesis. Curr Opin Hematol. 2002;9(2):93-100.
16. Pootrakul P, Sirankapracha P, Hemsorach S, et al. A correlation of erythrokinetics, ineffective erythropoiesis, erythroid precursor apoptosis in Thai patients with thalassemia. Blood. 2000;96(7):2606-2612.
17. Vichinsky E. Hemoglobin E syndromes. American Society of Hematology Education program, 2007:79-83.
18. Hajjar FM, Pearson HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr. 1994;125(3):490-492.
19. Fucharoen S, Siritanaratkul N, Winichagoon P, et al. Hydroxyurea increases Hb F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/Hb E disease. Blood. 1996;87(3):887-892.
20. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651.
21. Loukopoulos D, Voskaridou E, Stamoulakatou A, et al. Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci. 1998;850:120-128.
22. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99(1):10-14.
23. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039-2045.
24. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood. 1997;89(3):1078-1088.
25. Steinberg MH, Barton F, Castro O, et al. Effects of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651.
26. Wang WC, et al. A two year pilot trial of hydroxyurea in very young children with sickle cell anemia. J Pediatr. 2001;139:790-796.
27. Ferster C, Tahrir P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97(11):3628-3632.
28. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039-2045.
29. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW. Augmentation by erythropoietin of the fetal hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med. 1993;328(2):73-80.
30. DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood. 2002:99(11):3905-3908.
31. Ley TJ, DeSimone J, Anagou NP, et al. 5-Azacytidine selectively increases gamma-globin synthesis in a patient with beta-thalassemia. N Eng J Med. 1982;307(24):1469-1475
32. Dunbar C, Travis W, Kan YW, Nienhuis AW. 5-Azacytidine treatment in a beta (0)-thalassemic patient unable to be transfused due to multiple allo-antibodies. Br J Haematol. 1989;72:467-468
33. Lowrey CH, Nienhuis AW. Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia. N Eng J Med. 1993;329(12):845-848.
34. Ley TJ, DeSimone J, Noguchi CT. 5-azacytidine increases gamma globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood. 1983;62(2):370-380.
35. Koshy M, Dorn L, Bressler L, et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood. 2000;96(7):2379-2384.
36. Sauntharararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in sickle cell disease. Blood. 2003;102(12):3865-3870.
37. Perrine SP, Ginder G, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Eng J Med. 1993;328(2):129-131.
38. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999;93(6):1790-1797.
39. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood. 1994;84(1):339-343.
40. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta-thalassemia:a clinical trial. Blood. 1995; 85(1):39-34.
41. Ikuta T, Kan YW, Swerdlow PS, Faller DV, Perrine SP. Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy. Blood. 1998;92(8):2924-2933.
42. Cappellini MD, Graziadei G, Ciceri L, et al. Oral isobutyramide therapy in patients with thalassemia intermedia: Results of a phase II open study. Blood Cells Mol Dis. 2000;26:105-111.
43. Perrine SP, Yang YM, Piga A, et al. Butyrate + EPO in beta-thalassemia intermedia: interim findings of a phase II trial [abstract]. Blood. 2002;100:47a.
44. Perrine SP, Casteneda SA, Boosalis MS. White GL, Jones BM, Bohacek R. Induction of fetal globin in beta-thalassemia: cellular obstacles and molecular progress. Ann NY Acad Sci. 2005;1054:257-265.
45. Reich S, Bührer C, Henze G, et al. Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassemia. Blood. 2000;96(10):3357-3363.
46. Resar L, Segal J, Fitzpatric LK, Friedmann A, Brusilow S, Dover GJ. Induction of fetal Hemoglobin synthesis in children with sickle cell anemia on low dose oral sodium phenylbutyrate therapy. J Pediatr Hematol Oncol. 2002;24(9):737-741.
47. Olivieri NF, Rees DC, Ginder GD, et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet. 1997;350(9076):491-492.
48. Bourantas K, Economou G, Georgiou J. Administration of high doses of recombinant human erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial. Eur J Haematol. 1997;58(1):22-25.
49. Nisli G, Kavakli K, Vergin C, Oztop S, Cetingul N. Recombinant human erythropoietin trial in thalassemia intermedia. J Trop Pediatr. 1996;42:330-334.
50. Rachmilewitz EA, Aker M. The role of recombinant human erythropoietin in the treatment of thalassemia. Ann N Y Acad Sci. 1998;850:129-138.
51. Singer ST, Kuypers FA, Coates TD, et al. The effect of single and combination drug therapy on previously transfused E/beta-thalassemia patients: Implications on decision-making for therapy. Blood. 2002;100:119a-120a.
52. Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 1996;88:1576-1582
53. Constantoulakis P, Knitter G, Stamatoyannopoulos G. On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. Blood. 1989;74(6):1963-1971.
54. Boosalis MS, Bandyopadhyay R, Bresnick EH, et al. Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood. 2001;97(10):3259-3267.
55. Boosalis MS, Castaneda SA, Faller DV, Perrine SP. Expression of Bcl-family proteins in beta-thalassemia [abstract]. Blood. 2003;102:517a.
56. Pace BS, White GL, Dover GJ, Boosalis MS, Faller DV, Perrine SP. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood. 2002;100(13):4640-4648.
57. Dover GJ, Smith KD, Chang YC, Purvis S, Mays A, Meyers DA, Sheils C, Serjeant G. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2 Blood. 1992;80(3):816-824.
58. Labie D, Pagnier J, Lapoumerolie C, et al. Common haplotype dependency of Ggamma globin gene expression and high HbF levels in beta-thalassemia and sickle cell anemia patients. Proc Natl Acad Sci U S A. 1985;82(7):2111-2114.
59. Thein SL, Sampietro M, Rohde K, et al. Detection of a major gene for heterocellular heriditary persistence of fetal hemoglobin after accounting for genetic modifiers. Am J Hum Genet. 1994;54(2):214-228.
60. Chang YC, Smith KD, Moore RD, Serjeant GR, Dover GJ. An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the x-linked factors, beta globin haplotypes, alpha globin gene number, gender, and age. Blood. 1995;85(4):111-1117.
61. Garner C, Mitchel J, Hatzis T, Reittie J, Farrail M, Thein SL. Haplotype mapping of a major quantitative trait locus for fetal hemoglobin production on chromosome 6q23. Am J Hum Gen. 1998;62(6):1468-1474.
62. Steinberg MH, Kutlar A, Farrer LA, Baldwin CT. Fetal hemoglobin in sickle cell anemia: associations with single nucleotide polymorphisms in quantitative trait loci on chromosome 8q12 and Xp22. Blood. 2006;108:306a.
63. Jiang J, Best S, Menzel S, et al. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood. 2006;108(3):1077-1083.
64. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Eng J Med. 2005;352(21):2211-2221.